New Mexico Senate To Vote On Cannabis Legalization Bill

Despite some recent uncertainty, New Mexico seems to be gearing up for a vote on cannabis legalization.

from News – High Times https://ift.tt/3eTfIuV
via IFTTT

Seth Rogen’s new Houseplant cannabis unboxed and reviewed

My house smells terrific. I’ve spent several days sampling Seth Rogen’s new line of Houseplant cannabis, and the air in my place is spicy and fragrant. This weed is loud. The beloved comedic actor and stoner icon, along with his creative partner Evan Goldberg, launched Houseplant in California last week. They promptly broke the weed […]

The post Seth Rogen’s new Houseplant cannabis unboxed and reviewed appeared first on Leafly.

from Leafly https://ift.tt/3lvRqbu
via IFTTT

House Reintroduces SAFE Banking Act to Protect and Advance Legal Cannabis

House representatives have reintroduced the SAFE Banking Act in a push to allow cannabis businesses to have access to banking services.

from News – High Times https://ift.tt/3sdfWAI
via IFTTT

Gummies, tinctures, and a whole lot more for the people

Leafly takes a look at some stand-out products from the quality freaks at Koi CBD to show how they're setting the bar high in quality and consistency

The post Gummies, tinctures, and a whole lot more for the people appeared first on Leafly.

from Leafly https://ift.tt/3eQidOE
via IFTTT

New PTSD study finds cannabis safe, but not as effective as assumed

Many factors could be at play: the placebo effect, poor quality weed, subject pool, or maybe it just doesn't work as well as some assume.

The post New PTSD study finds cannabis safe, but not as effective as assumed appeared first on Leafly.

from Leafly https://ift.tt/3vyzeTv
via IFTTT

Michigan Cracks Down on Cannabis Banking Through Credit Unions

In the U.S., banks and credit unions are reluctant to work with cannabis businesses because of the federal illegality of cannabis.

from News – High Times https://ift.tt/3bZAE1v
via IFTTT

Largest Human Trial to Date Reviews Safety of Full Spectrum Hemp Products

In January 2019, the European Union (EU) reclassified extracts of Cannabis sativa L. and derived products containing cannabinoids, including CBD, as “Novel Food” under the EU Novel Food Catalogue. The reclassification was based on the lack of demonstrated history of human consumption of these extracts and of any product to which they might be added.

As one would naturally suspect, the Novel Food Application process is time consuming and expensive. Every successful Novel Food Application goes through three phases (the “Application Assessment,” the “Safety Assessment” and the “Marketing Authorization”), which lasts 3 to 4 years and require a hefty budget of €350,000 to €500,000.

To alleviate to burdensome cost of an individual Novel Food Application, the European Industrial Hemp Association (EIHA), which represents and advocate for the interest of European hemp producers and processors, launched a Novel Food Consortium (the Consortium). The Consortium was established to submit joint Novel Food applications and share the costs between its members, the majority of which are small and medium-sized enterprises (SMEs) that could not bear the cost of an individual application.

To date EIHA has submit three categories of Novel Food applications, including one for CBD-isolate-based products, another for synthetic-CBD-based products and a third one for products infused with full spectrum hemp extract. For each of these applications, EIHA will need to submit toxicological studies showing the substances are safe for human consumption, yet the organization seems particularly concerned with that of full spectrum hemp extract-based products.

In a recent interview with Cannabis Health, EIHA’s Managing Director, Lorenza Romanese explained that the challenge lays in the presence of tetrahydrocannabinol (THC) in the full spectrum hemp extract.

As is the case in the United States, Europe lacks sufficiently reliable scientific data to support the safety of products infused with full spectrum hemp extract, including the safety of THC, one of the 100+ cannabinoids naturally found in the extract. Therefore, through its collective effort, EIHA is taking the lead on investing in the type of comprehensive research the industry so desperately needs to freely operate by spearheading the largest human trial to date on the safety of consuming trace amounts of THC.

EIHA hopes that this toxicological study, which will assess 200 participants during a 30-day period, will make regulators more comfortable with the concept of full spectrum hemp extract and will enable EIHA members to continue producing and selling these products on the European market and overseas.

Nevertheless, there remains a possibility that European regulators will reject the validity of the study during the Assessment Phase of the Novel Food Application process, in which case EIHA is prepared to appeal.

Once submitted, the European Food Safety Authority (EFSA), the Food and Drug Administration’s European counterpart, will have 9 months to carry out the safety assessment of EIHA’s toxicological study, at which point the EFSA will issue an opinion to the EU Commission. If favorable, the EU Commission will submit a draft of an implementing regulation approving products infused with full spectrum hemp extract to the Standing Committee on Plants, Animals, Food and Feed, which would then add these products to the EU Novel Food Catalogue.

Needless to say, such approval would be a game changer for the industry. We’ll continue to monitor and report on the development of this ground-breaking study so stay tuned!

The post Largest Human Trial to Date Reviews Safety of Full Spectrum Hemp Products appeared first on Harris Bricken.

from Canna Law Blog – Harris Bricken https://ift.tt/2P694GZ
via IFTTT